Brodalumab for the treatment of plaque psoriasis in a real-life setting: a 3 years multicenter retrospective study-IL PSO (Italian landscape psoriasis)

被引:26
作者
Gargiulo, Luigi [1 ,2 ]
Ibba, Luciano [1 ,2 ]
Malagoli, Piergiorgio [3 ]
Amoruso, Fabrizio [4 ]
Argenziano, Giuseppe [5 ]
Balato, Anna [5 ]
Bardazzi, Federico [6 ]
Burlando, Martina [7 ]
Carrera, Carlo Giovanni [8 ]
Damiani, Giovanni [9 ]
Dapavo, Paolo [10 ]
Dini, Valentina [11 ]
Fabbrocini, Gabriella [12 ]
Franchi, Chiara [9 ]
Gaiani, Francesca Maria [4 ]
Girolomoni, Giampiero [13 ]
Guarneri, Claudio [14 ]
Lasagni, Claudia [15 ]
Loconsole, Francesco [16 ]
Marzano, Angelo Valerio [8 ,17 ]
Megna, Matteo [12 ]
Sampogna, Francesca [18 ]
Travaglini, Massimo [19 ]
Costanzo, Antonio [1 ,2 ]
Narcisi, Alessandra [1 ]
机构
[1] IRCCS Humanitas Res Hosp, Dermatol Unit, Milan, Italy
[2] Humanitas Univ, Dept Biomed Sci, Milan, Italy
[3] Azienda Osped San Donato Milanese, Dept Dermatol, Dermatol Unit, Milan, Italy
[4] Azienda Osped Cosenza, Dermatol Unit, Cosenza, Italy
[5] Univ Campania L Vanvitelli, Dermatol Unit, Naples, Italy
[6] IRCCS Azienda Osped Univ Bologna, Dermatol Unit, Policlin S Orsola Malpighi, Bologna, Italy
[7] Univ Genoa, Dept Dermatol, IRCCS Osped Policlin San Martino, Dipartimento Sci Salute DISSAL, Genoa, Italy
[8] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Dermatol Unit, Milan, Italy
[9] Univ Milan, Dept Biomed Surg & Dent Sci, Milan, Italy
[10] Univ Turin, Dept Biomed Sci & Human Oncol, Dermatol Clin 2, Turin, Italy
[11] Osped Santa Chiara, Dept Clin & Expt Med, Dermatol Unit, Pisa, Italy
[12] Univ Naples Federico II, Dermatol Sect, Dept Clin Med & Surg, Naples, Italy
[13] Univ Verona, Sect Dermatol & Venereol, Dept Med, Verona, Italy
[14] Univ Messina, Dept Biomed & Dent Sci & Morphofunct Imaging, Unit Dermatol, AOU Policlin G Martino, Messina, Italy
[15] Univ Modena, Dept Specialized Med, Dermatol Clin, Modena, Italy
[16] Univ Bari, Dept Dermatol, Bari, Italy
[17] Univ Milan, Dept Pathophysiol & Transplantat, Milan, Italy
[18] Ist Dermopat Immacolata IDI IRCCS, Clin Epidemiol Unit, Rome, Italy
[19] Osped Perrino, UOSD Dermatol, Ctr Cura Psoriasi, Brindisi, Italy
关键词
brodalumab; psoriasis; psoriasis treatment; psoriatic arthritis; real-life;
D O I
10.3389/fmed.2023.1196966
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
IntroductionBrodalumab is a monoclonal antibody that targets the subunit A of the interleukin-17A receptor (IL17RA), inhibiting the signaling of various isoforms of the IL-17 family. It has been approved for the treatment of moderate-to-severe plaque psoriasis after being evaluated in three Phase-3 trials. However, long-term data on brodalumab in a real-life setting are still limited. MethodsThe aim of this study was to evaluate the long-term effectiveness and safety of brodalumab in psoriasis. We also assessed the drug survival of brodalumab in a 3 years timespan. We conducted a retrospective multicenter study on 606 patients followed up at 14 Italian dermatology units, all treated with brodalumab according to Italian guidelines. Patients' demographics and disease characteristics were retrieved from electronic databases. At baseline and weeks 12, 24, 52, 104 and 156, we evaluated the psoriasis area and severity index (PASI) score and investigated for adverse events. The proportions of patients reaching 75, 90 and 100% (PASI 75, PASI 90 and PASI 100, respectively) improvement in PASI, compared with baseline, were also recorded. ResultsAt week 12, 63.53% of the patients reached PASI 90 and 49.17% PASI 100. After 3 years of treatment, 65.22% of patients maintained a complete skin clearance, and 91.30% had an absolute PASI of 2 or less. Patients naive to biological therapies had better clinical responses at weeks 12, 24 and 52. However, after 2 years of treatment, no significant differences were observed. Body mass index did not interfere with the effectiveness of brodalumab throughout the study. No new safety findings were recorded. After 36 months, 85.64% of our patients were still on treatment with brodalumab. ConclusionOur data confirm the effectiveness and the safety of brodalumab in the largest real-life cohort to date, up to 156 weeks.
引用
收藏
页数:10
相关论文
共 50 条
[41]   Achievement and maintenance of therapeutic response to brodalumab in patients with moderate-to-severe plaque psoriasis: An Italian, observational, retrospective and prospective study (BRIGHT study) [J].
Dapavo, Paolo ;
Fabbrocini, Gabriella ;
Campione, Elena ;
Giofre, Claudia ;
Balato, Anna ;
Potenza, Concetta ;
Dastoli, Stefano ;
Malagoli, Piergiorgio ;
Offidani, Annamaria ;
Bardazzi, Federico ;
Peris, Ketty ;
Pella, Paolo ;
De Pasquale, Rocco ;
Bonifati, Claudio ;
Giacchetti, Alfredo ;
Pallotta, Sabatino ;
Congedo, Maurizio ;
Amerio, Paolo ;
Fargnoli, Maria Concetta ;
Pinton, Piergiacomo Calzavara ;
Venturini, Marina .
JEADV CLINICAL PRACTICE, 2023, 2 (04) :739-752
[42]   Fast Clinical Response of Bimekizumab in Nail Psoriasis: A Retrospective Multicenter 36-Week Real-Life Study [J].
Campione, Elena ;
Artosi, Fabio ;
Shumak, Ruslana Gaeta ;
Giunta, Alessandro ;
Argenziano, Giuseppe ;
Assorgi, Chiara ;
Balato, Anna ;
Bernardini, Nicoletta ;
Brunasso, Alexandra Maria Giovanna ;
Burlando, Martina ;
Caldarola, Giacomo ;
Campanati, Anna ;
Carugno, Andrea ;
Castelli, Franco ;
Conti, Andrea ;
Costanzo, Antonio ;
Cuccia, Aldo ;
Dapavo, Paolo ;
Dattola, Annunziata ;
De Simone, Clara ;
Di Lernia, Vito ;
Dini, Valentina ;
Donini, Massimo ;
Errichetti, Enzo ;
Esposito, Maria ;
Fargnoli, Maria Concetta ;
Foti, Antonio ;
Fiorella, Carmen ;
Gargiulo, Luigi ;
Gisondi, Paolo ;
Guarneri, Claudio ;
Legori, Agostina ;
Lembo, Serena ;
Loconsole, Francesco ;
Malagoli, Piergiorigio ;
Marzano, Angelo Valerio ;
Mercuri, Santo Raffaele ;
Megna, Matteo ;
Micali, Giuseppe ;
Mortato, Edoardo ;
Musumeci, Maria Letizia ;
Narcisi, Alessandra ;
Offidani, Anna Maria ;
Orsini, Diego ;
Paolino, Giovanni ;
Pellacani, Giovanni ;
Peris, Ketty ;
Potenza, Concetta ;
Prignano, Francesca ;
Quaglino, Pietro .
PHARMACEUTICALS, 2024, 17 (10)
[43]   Psoriasis in Childbearing Age: A Real-Life, Retrospective, Single-Center Study on Anti-IL17 and IL-23 Agents [J].
Borriello, Silvia ;
Roccuzzo, Gabriele ;
Dapavo, Paolo ;
Sciamarrelli, Nadia ;
Macagno, Nicole ;
Leo, Francesco ;
Quaglino, Pietro ;
Ribero, Simone ;
Mastorino, Luca .
JOURNAL OF CLINICAL MEDICINE, 2024, 13 (21)
[44]   Risankizumab for the Treatment of Moderate-to-Severe Psoriasis: Real-Life Multicenter Experience from the Czech Republic [J].
Gkalpakiotis, Spyridon ;
Cetkovska, Petra ;
Arenberger, Petr ;
Dolezal, Tomas ;
Arenbergerova, Monika ;
Velackova, Barbora ;
Fialova, Jorga ;
Kojanova, Martina .
DERMATOLOGY AND THERAPY, 2021, 11 (04) :1345-1355
[45]   Secukinumab in moderate-to-severe plaque psoriasis: a multi-center, retrospective, real-life study up to 52 weeks observation [J].
Galluzzo, Marco ;
Talamonti, Marina ;
De Simone, Clara ;
D'Adamio, Simone ;
Moretta, Gaia ;
Tambone, Sara ;
Caldarola, Giacomo ;
Fargnoli, Maria Concetta ;
Peris, Ketty ;
Bianchi, Luca .
EXPERT OPINION ON BIOLOGICAL THERAPY, 2018, 18 (07) :727-735
[46]   Risankizumab for the Treatment of Moderate-to-Severe Psoriasis: Real-Life Multicenter Experience from the Czech Republic [J].
Spyridon Gkalpakiotis ;
Petra Cetkovska ;
Petr Arenberger ;
Tomas Dolezal ;
Monika Arenbergerova ;
Barbora Velackova ;
Jorga Fialova ;
Martina Kojanova .
Dermatology and Therapy, 2021, 11 :1345-1355
[47]   Patient satisfaction with calcipotriol/betamethasone dipropionate cutaneous foam for the treatment of plaque psoriasis: The LION real-life multicenter prospective observational cohort study [J].
Campanati, Anna ;
Atzori, Laura ;
Potenza, Concetta ;
Damiani, Giovanni ;
Bianchi, Luca ;
Corazza, Monica ;
Tiberio, Rossana ;
Prignano, Francesca ;
Argenziano, Giuseppe ;
Fargnoli, Maria Concetta ;
Stingeni, Luca ;
Mazzotta, Annamaria ;
De Pita, Ornella ;
Mazzatenta, Carlo ;
Feliciani, Claudio ;
Donini, Massimo ;
Offidani, Annamaria ;
Peris, Ketty .
DERMATOLOGIC THERAPY, 2021, 34 (05)
[48]   Secukinumab in Patients with Psoriasis and a Personal History of Malignancy: A Multicenter Real-Life Observational Study [J].
Cristina Pellegrini ;
Maria Esposito ;
Ernesto Rossi ;
Paolo Gisondi ;
Stefano Piaserico ;
Paolo Dapavo ;
Andrea Conti ;
Alessio Gambardella ;
Martina Burlando ;
Alessandra Narcisi ;
Annamaria Offidani ;
Riccardo Balestri ;
Federico Bardazzi ;
Francesca Prignano ;
Cristina Mugheddu ;
Marco Romanelli ;
Giovanna Malara ;
Giovanni Schinzari ;
Maria Concetta Fargnoli .
Dermatology and Therapy, 2022, 12 :2613-2626
[49]   Secukinumab in Patients with Psoriasis and a Personal History of Malignancy: A Multicenter Real-Life Observational Study [J].
Pellegrini, Cristina ;
Esposito, Maria ;
Rossi, Ernesto ;
Gisondi, Paolo ;
Piaserico, Stefano ;
Dapavo, Paolo ;
Conti, Andrea ;
Gambardella, Alessio ;
Burlando, Martina ;
Narcisi, Alessandra ;
Offidani, Annamaria ;
Balestri, Riccardo ;
Bardazzi, Federico ;
Prignano, Francesca ;
Mugheddu, Cristina ;
Romanelli, Marco ;
Malara, Giovanna ;
Schinzari, Giovanni ;
Fargnoli, Maria Concetta .
DERMATOLOGY AND THERAPY, 2022, 12 (11) :2613-2626
[50]   Real-Life Effectiveness and Safety of Risankizumab in 131 Patients Affected by Moderate-to-Severe Plaque Psoriasis: A 52-Week Retrospective Study [J].
Gargiulo, Luigi ;
Ibba, Luciano ;
Pavia, Giulia ;
Vignoli, Carlo Alberto ;
Piscazzi, Francesco ;
Valenti, Mario ;
Sanna, Federica ;
Perugini, Chiara ;
Avagliano, Jessica ;
Costanzo, Antonio ;
Narcisi, Alessandra .
DERMATOLOGY AND THERAPY, 2022, 12 (10) :2309-2324